Graig Suvannavejh
Stock Analyst at Mizuho
(4.52)
# 281
Out of 5,149 analysts
174
Total ratings
54.55%
Success rate
21.6%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $131.51 | +90.10% | 2 | Feb 25, 2026 | |
| INSM Insmed | Maintains: Outperform | $211 → $204 | $147.00 | +38.78% | 13 | Feb 24, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $5.60 | +78.57% | 1 | Feb 19, 2026 | |
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $8.15 | +71.78% | 1 | Feb 9, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $14.10 | -64.54% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $41.51 | +30.09% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $167.88 | +15.56% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $28.27 | +62.72% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $76.55 | +30.63% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $9.84 | +133.74% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $69.40 | -19.31% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $34.31 | +34.07% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $164.05 | +23.13% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $20.16 | -5.75% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.60 | +150.00% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.35 | +8,454.32% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.11 | +65.88% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.06 | +63.40% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.95 | +102.02% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $17.53 | -37.25% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $18.32 | +41.92% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.11 | -43.30% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.36 | +1.98% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.62 | +369.14% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $8.21 | +801.34% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.64 | -62.12% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $89.56 | -60.92% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $26.44 | -69.74% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $60.72 | -6.13% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $28.88 | -82.69% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.25 | +231.71% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.00 | +180.00% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $28.81 | +7.60% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $14.95 | +2,441.81% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.58 | +200.63% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $23.60 | +52.54% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.05 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.63 | +1,306.84% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $186.67 | -31.43% | 1 | Sep 14, 2020 |
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $131.51
Upside: +90.10%
Insmed
Feb 24, 2026
Maintains: Outperform
Price Target: $211 → $204
Current: $147.00
Upside: +38.78%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $5.60
Upside: +78.57%
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $8.15
Upside: +71.78%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $14.10
Upside: -64.54%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $41.51
Upside: +30.09%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $167.88
Upside: +15.56%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $28.27
Upside: +62.72%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $76.55
Upside: +30.63%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.84
Upside: +133.74%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $69.40
Upside: -19.31%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $34.31
Upside: +34.07%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $164.05
Upside: +23.13%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $20.16
Upside: -5.75%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.60
Upside: +150.00%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.35
Upside: +8,454.32%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.11
Upside: +65.88%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.06
Upside: +63.40%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.95
Upside: +102.02%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $17.53
Upside: -37.25%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $18.32
Upside: +41.92%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.11
Upside: -43.30%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.36
Upside: +1.98%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.62
Upside: +369.14%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $8.21
Upside: +801.34%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.64
Upside: -62.12%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $89.56
Upside: -60.92%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $26.44
Upside: -69.74%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $60.72
Upside: -6.13%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $28.88
Upside: -82.69%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.25
Upside: +231.71%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.00
Upside: +180.00%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $28.81
Upside: +7.60%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $14.95
Upside: +2,441.81%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.58
Upside: +200.63%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $23.60
Upside: +52.54%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $33.05
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.63
Upside: +1,306.84%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $186.67
Upside: -31.43%